Ocugen Inc OCGN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EDT
1.73quote price arrow up+0.01 (+0.58%)
Volume
112,054
Close
1.72quote price arrow down-0.13 (-7.03%)
Volume
6,349,180
52 week range
0.34 - 2.11
Loading...
  • Open1.83
  • Day High1.84
  • Day Low1.68
  • Prev Close1.85
  • 52 Week High2.11
  • 52 Week High Date03/25/24
  • 52 Week Low0.34
  • 52 Week Low Date10/26/23

Key Stats

  • Market Cap442.604M
  • Shares Out257.33M
  • 10 Day Average Volume8.13M
  • Dividend-
  • Dividend Yield-
  • Beta3.62
  • YTD % Change199.13

KEY STATS

  • Open1.83
  • Day High1.84
  • Day Low1.68
  • Prev Close1.85
  • 52 Week High2.11
  • 52 Week High Date03/25/24
  • 52 Week Low0.34
  • 52 Week Low Date10/26/23
  • Market Cap442.604M
  • Shares Out257.33M
  • 10 Day Average Volume8.13M
  • Dividend-
  • Dividend Yield-
  • Beta3.62
  • YTD % Change199.13

RATIOS/PROFITABILITY

  • EPS (TTM)-0.24
  • P/E (TTM)-7.21
  • Fwd P/E (NTM)-7.41
  • EBITDA (TTM)-59.287M
  • ROE (TTM)-110.32%
  • Revenue (TTM)7.05M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-829.84%
  • Debt To Equity (MRQ)9.35%

EVENTS

  • Earnings Date08/19/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ocugen Inc

 

Profile

MORE
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for...
Shankar Musunuri Ph.D.
Chairman of the Board, Chief Executive Officer
Michael Breininger
Principal Financial Officer, Interim Chief Accounting Officer
Address
11 GREAT VALLEY PARKWAY
Malvern, PA
19355
United States

Top Peers

SYMBOLLASTCHG%CHG
ABSI
Absci Corp
4.61-0.18-3.76%
FULC
Fulcrum Therapeutics Inc
7.71+0.07+0.92%
CRBP
Corbus Pharmaceuticals Holdings Inc
44.96-0.24-0.53%
KALV
Kalvista Pharmaceuticals Inc
11.69+0.08+0.69%
FATE
Fate Therapeutics Inc
3.65-0.05-1.35%